Btg Share Discussion Threads

[spyder] 19/5/2017 20:07

--> CT
ahhh! That would make more sense. I was reading a transcript, obviously an error in translation.

[cockneytrader] 19/5/2017 19:59

"and we don't take Varithena to Europe".

[spyder] 19/5/2017 18:30

--> Dr.B The chart suggests this will go one way or another!! Actually, from my novice perspective, it looks to me like if the recent breakout is to conthere should be support from around these levels.
However, if the levels don't hold and the support gives, then we are back in the previous miserable trading range.
--> Did anyone else hear/read the analysts presentation? There is some interesting stuff in there, a couple of highlights:
1) Varithena SG&A = aaprx £20m
2) Very strong growth from TheraSphere and doing very well against Sirtex
3) No suggestion of revenue concerns with DigiFab
4) EKOS ACCESS PTS results out around 15 June, if good, will lead to expansion of markets/cases. 'PTS' means something quite different in my world!
5) OPTALISE PE results due next week (21 may), if good will also expand the market.
6) At one point it looks like LM said "and of course, we then take Varithena to Europe", I had missed that Varithena would go to Europe, I was under the impression that for some reason the European market was undesirable for Var.
7)Varithena CPT codes published in Q4 LM - "we do now have clarity that we will get the codes". THe interesting bit will be the $ numbers attached to the codes and what happens to other similar treatment modalities that are being reviewed at the same time.
8) Zytiga royalties to 2027, generics in US from Oct 2018 and EU 2021.
Happy weekend!

[dr biotech] 19/5/2017 17:07

Well I am in today. That's normally a sell sign...

[a1ord53] 19/5/2017 17:01

Where is Afrodite with fifth wave ?
This kind of charting doesnt work with BTG imo.

[bargainbob] 18/5/2017 19:20

thats what i was warning about novice :-)

[nervousnovice] 18/5/2017 15:10

So glad I sold before results at 730p if only all my trades were as satisfactory!

[barriew] 18/5/2017 13:50

I wish i had sold some pre results, i sold half yesterday as can only seeing it drift untill the next resulrs are due, ill buy back sub 6£ if we get that low again,

[fhmktg] 18/5/2017 12:14

Every time we go through this post results cycle it hurts and annoys me.It makes the Labour idea of a transaction tax seem pretty attractive....never thought I would say that!

[broadwood] 16/5/2017 16:02

Specialist healthcare company BTG reported a drop in full-year pre-tax profit on Tuesday as it said translation benefits from a weaker sterling were offset by hedging losses on forward contracts.
For the year to the end of March, the company made a pre-tax profit of £31.6m versus £57.5m the year before, despite revenue rising to £570.5m from £447.5m.

Product sales were up 37% to £387.3m while licensing revenues grew 12% to £183.2m and BTG said Interventional Medicine is now the largest and fastest growing revenue contributor, delivering 15% organic growth at constant exchange rates.

Chief executive officer Louise Makin said: "We have delivered strong double-digit product sales growth and generated significant cash flows, enabling us to invest in product innovation, clinical data, geographic expansion and acquisitions. We have a broad portfolio and a scalable platform, and there is momentum across the business. With the financial strength to continue our investment plans, we are well positioned to capture further value in the growing Interventional Medicine space and to deliver sustained business growth."

The group said it expects to deliver continued double-digit product sales growth beyond 2017/18, driven by a strong Interventional Medicine performance, aided by the anticipated opportunity from Varithena and PneumRx. In addition, it expects a sustained performance in Specialty Pharmaceuticals to underpin product sales over the medium term.

[aphrodites] 16/5/2017 14:49

There is nothing wrong with the trading statement or figures today and the company is performing well and above expectations.

One can never build into the projected figures the cost of hedging not performing as expected. On the other hand, if no protection is taken against currency exposures the company gets kicked for not doing so.
I understand that a Hedge Fund might have taken out a short in the last few days backed by a purchase of shares in another company. The fund would have an interest in seeing the price lower today and is more than likely still trading with a sell bias. This has resulted in an overreaction in today’s fall. But it has to buy back again!

The set-back in the price fits ideally into my 5-wave pattern although todays fall is slightly more than I expected. The 10% fall in the price from £7.30 down to the £6.50 region will have marked the second downward leg in my sequence of 5 waves. We should start to move up from here in wave 3 which is usually the strongest wave in the sequence of 5.

I bought shares at £6.50 today and will look at add as the price moves upwards again.

[a1ord53] 16/5/2017 12:18

Anybody knows if they hedged exchange rate for new FY ?
They were promising 26% growth until 2022 and now midteens - ????

[gregsc] 16/5/2017 11:25

May recover a bit when the Americans wake up.

[fhmktg] 16/5/2017 10:36

Traders having a field day!

[dr biotech] 16/5/2017 08:59

According to Bloomberg this was called up before the market opened. Not wholly sure what to make of the drop, whether its a buying opportunity or there is something a touch concerning. I don't have a position here yet but its a company that I have a natural interest in.

[waterloo01] 16/5/2017 08:50

I can understand the weakness and unusual for them not to put in £££; guidance? Varithena still not taken off and unlikely to see much until 2018 (so 1st half results 2018). License revenue weak going forward as expected and concerns re snake bite competition expected in 2018(see seeking alpha article). Hedging loses etc don't help.

I'll watch from the sidelines for 2017.

[steeplejack] 16/5/2017 08:44

Yes,the underlying business is fine.As much as they'd like to bury the £53.3m adverse impact of hedging losses and the fine,it takes the shine off a very sound underlying performance with continuing strong cash flow generation.

[fhmktg] 16/5/2017 08:11

Due to the fine and currency.Underlying growth remains strong and optimistic.Resolution of coding for V, now promised for January and approval for PneumRx by the FDA are the spurs for next year.The effects of the currency hedging will go and the impressive growth of interventional sector will come through in the next six month report.Keep the faith!

[spyder] 16/5/2017 07:35

I'm not sure these results are good enough to sustain the recent surge, but who knows.
There is no total revenue projection (that I could see), I wonder what that means?
They still seem to be optimistic about Varithena, albeit on £4m of sales last year.